Special considerations in conducting clinical trials of chronic pain management interventions in children and adolescents and their families

Tonya M. Palermo\textsuperscript{a,b,*}, Susmita Kashikar-Zuck\textsuperscript{c,d}, Stefan J. Friedrichsdo\textsuperscript{r}, Scott W. Powers\textsuperscript{c,d}

Abstract

Introduction: Disabling chronic pain is a common experience for children and adolescents. However, the evidence base for chronic pain interventions for youth is extremely limited, which has hindered the development of evidence-based practice guidelines for most pediatric chronic pain conditions.

Objectives: To review and provide recommendations on clinical trial design and evaluation in children and adolescents with chronic pain.

Methods: In this article, we summarize key issues and provide recommendations for addressing them in clinical trials of chronic pain interventions in children and adolescents and their families.

Results: To stimulate high-quality trials of pediatric chronic pain management interventions, attention to key issues including sample characterization, trial design and treatment administration, outcome measurement, and the ethics of intervening with children and adolescents, as opposed to adults with chronic pain, is needed.

Conclusion: Future research to develop interventions to reduce or prevent childhood chronic pain is an important priority area, and requires special considerations in implementation and evaluation in clinical trials.

Keywords: Chronic pain, Clinical trials, Children and adolescents

1. Introduction

1.1. Prevalence and impact of pediatric chronic pain

Pain that persists for longer than 3 months in children and adolescents is common; epidemiological studies estimate that 5% to 8% of children have severe and disabling chronic pain.\textsuperscript{40} The functional consequences of chronic pain on children and adolescents are reflected in missed school days, limited social and athletic activities, and emotional distress.\textsuperscript{59} Indeed, the costs of chronic pain include not only reduced quality of life for children but also lost work productivity and high costs to parents and caregivers. The total direct cost of moderate–severe pediatric chronic pain in the United States is extrapolated to $19.5 billion per year.\textsuperscript{33} Because longitudinal data demonstrate that childhood chronic pain places individuals at significant risk of developing or continuing with chronic pain, physical symptoms, and psychiatric complaints into adulthood,\textsuperscript{96} effective treatment of pain in childhood is critical for preventing or lessening the enormous societal impact of adult chronic pain.

Chronic pain includes persistent (ongoing) and recurrent (episodic) pain in children with underlying health conditions (eg, inflammatory bowel disease, sickle cell disease [SCD], juvenile idiopathic arthritis) and primary pain disorders (eg, primary headaches, centrally mediated abdominal pain syndrome, widespread musculoskeletal pain) as well as complex regional pain syndrome.\textsuperscript{29,79} A significant number of children experience both entities, ie, “acute-on-chronic” pain such as children with SCD who may have ongoing daily widespread pain superimposed with acute vaso-occlusive pain exacerbations. Clinical studies have also demonstrated altered pain pathways in the central nervous system associated with overall heightened pain sensitivity (thought to be a central sensitization phenomenon) in patients with many types of localized and diffuse chronic pain syndromes such as chronic low back pain, neck pain, headaches, widespread musculoskeletal pain, and irritable bowel syndrome.\textsuperscript{29,88}

1.2. Chronic pain interventions in children and adolescents

Our goal in this review is to provide a comprehensive overview of special considerations in designing and conducting clinical trials...
for chronic pain interventions in children and adolescents. Chronic pain interventions for children and adolescents encompass a variety of single and multi-modal treatments including pharmacological (eg, analgesics, antidepressants, anticonvulsants, antimigraine medications), psychological (eg, cognitive-behavioral therapy), physical therapy (eg, aerobic exercise, strengthening, graded motor imagery), and complementary and integrative health interventions (eg, biofeedback, self-hypnosis, yoga). Treatments have been delivered in different settings including the home,\textsuperscript{1,29,38,66,76} in schools,\textsuperscript{29,52} in outpatient clinics,\textsuperscript{66,73,80} in hospitals,\textsuperscript{31} and in inpatient intensive rehabilitation settings.\textsuperscript{20,38,55,56,64} Although many of these interventions are routinely used in clinical care, most have not been tested in rigorous trials in pediatric populations.

Despite the high prevalence, cost, and impact of chronic pain in the general population, the evidence base for chronic pain interventions is very limited. This is particularly pronounced for clinical trials of pediatric chronic pain interventions. Children have historically been underrepresented in all clinical trials compared with adults. Adult publications of randomized controlled trials (RCTs) are increasing at a faster rate than pediatric RCTs (90.5 RCTs per year vs 16.9 RCTs per year) in almost all specialties.\textsuperscript{11} For example, in one analysis among registered clinical drug trials, although 59.9\% of the disease burden for 9 selected conditions was attributable to children, only 12.0\% of trials were pediatric.\textsuperscript{8} Fewer pediatric trials are funded by industry and thus, most investigations rely on funding from government and nonprofit organizations.\textsuperscript{8} As another example of the limited pediatric chronic pain intervention research, the Cochrane Pain, Palliative and Supportive Care Review Group contains only 13 titles devoted to chronic noncancer pain in children compared with over 150 titles in adults. Lack of data on treatment efficacy has hindered the development of evidence-based treatment guidelines for most pediatric chronic pain conditions.

The lack of high-quality trials testing the full range of treatment options specifically for children and adolescents with chronic pain is a major concern. Indeed, the United States Federal Pain Research Strategy (https://iprcc.nih.gov/sites/default/files/FPRS_Research_Recommendations_Final_508C.pdf) has specifically prioritized the understanding of mechanisms of childhood chronic pain and effective chronic pain management in children. Children are not simply "little adults" and application of pharmacologic and nonpharmacologic treatments that are based on evidence from adult studies can often be inappropriate. For example, differences in pharmacodynamics, pharmacokinetics, and pharmacogenomics in a developing nervous system may result in suboptimal effects, adverse drug responses, and toxicity. Despite recognition of the need to conduct trials of medicines used in children and legislation to facilitate this, there continue to be a dearth of pediatric trials.\textsuperscript{8} Particularly concerning, Bourgeois et al.\textsuperscript{8} found a relative paucity of registered pharmacokinetic/dynamic and safety assessments in clinical trials conducted in children compared with adults. Clearly, more attention to this area is needed. In addition to biologic differences, psychosocial and developmental factors in pediatric populations are unique and must be considered in designing nonpharmacologic intervention studies.\textsuperscript{85} Although there are a larger number of trials of integrative (nonpharmacologic), primarily psychological interventions for pediatric chronic pain, the quality of these trials for the most part has been low due to numerous methodological limitations.

Fortunately, there has been a growing interest in stimulating high-quality trials of pediatric pain management interventions and recognition that differences exist in sample characterization, trial design and treatment administration, outcome measurement, and in the ethics of clinical trials with children and adolescents, as opposed to adults with chronic pain. Acute pain interventions for children have been considered separately and other groups have defined unique considerations in conducting acute pain trials in children.\textsuperscript{7} However, less attention has been devoted to the special considerations in clinical trials of pediatric chronic pain interventions with the exception of recommendations on selection of core outcome domains and measures for clinical trials of pediatric chronic pain management interventions (Ped-IMMPACT).\textsuperscript{57} Furthermore, some basic considerations in clinical trial methodology for children and adolescents with headache have been published.\textsuperscript{2} In this article, we discuss special considerations and provide recommendations concerning the conduct of clinical trials for chronic pain interventions in children and adolescents and their families.

2. Sample characterization

Important differences between children and adults exist in the signs, symptoms, and diagnosis of chronic pain conditions as well as the availability of samples. Some chronic pain conditions that are well-characterized in adulthood such as temporomandibular joint disorder and chronic low back pain are not as prevalent in childhood\textsuperscript{29,50} and others (such as widespread musculoskeletal pain/juvenile fibromyalgia) may not have the identical clinical signs, symptoms, and comorbidities as in adults.\textsuperscript{45} An issue that arises in pediatric trials is the clarity and precision with which pediatric pain diagnoses/subtypes are defined in a research study. In contrast to most trials in adult chronic pain, which typically focus on a single pain condition (eg, chronic low back pain, fibromyalgia, migraine), treatment studies in children vary greatly in terms of whether they include a heterogeneous sample of pediatric pain conditions (including headache disorders, abdominal pain, regional or widespread musculoskeletal pain) or more narrowly defined single pain conditions. This is due to the combined issues of the lack of available consensus definitions of pediatric chronic pain disorders, the limited number of treatment centers, paucity of funding for pediatric trials, and in some instances, smaller available samples. Consensus definitions of chronic pain conditions exist for a few conditions that tend to have a high prevalence in pediatric populations such as functional abdominal pain\textsuperscript{49} and primary headaches (tension headaches and migraines)\textsuperscript{37} and correspondingly, there are more single condition trials within these conditions. Overlapping pain conditions (ie, presence of more than one chronic pain condition such as migraine and irritable bowel syndrome) are also of importance in both pediatric and adult pain research and care, but consensus is lacking on classification. There is a need for more clarity in classification of pediatric pain conditions to increase understanding of treatment response in well-defined patient groups. Ideally, this would also allow for studying longitudinal trajectories of pediatric with related adult syndromes to understand whether pain interventions are effective across the lifespan. The ability to connect pediatric to adult pain conditions through classification is particularly important during the developmental transition from older adolescence to young adulthood, when care shifts to adult pain care providers.\textsuperscript{75}

There are clearly advantages and disadvantages to each of these diagnostic approaches. Heterogeneous samples allow for greater ease of recruitment and generalizability of findings, whereas focusing on specific pain subtypes allows for tailoring of treatment for the specific condition and examination of potential mechanistic factors and response in well-specified subgroups. The lack of consistency in diagnostic terminology
complicates the issues at hand further. The field needs more clarity in terms of classification of pediatric chronic pain conditions because this equally impacts the design and interpretation of trials of pharmacological and integrative (non-pharmacological) interventions, singly or in combination.

2.1. Pain classification

Progress has been made in pain classification that may improve efforts to characterize pediatric pain samples such as through the recent publication of an evidence-based chronic pain classification system, the ACTTION-APS Pain Taxonomy (AAPT).28 The resultant pain taxonomy framework developed through this initiative incorporates knowledge of biopsychosocial mechanisms and classifies chronic pain conditions along 5 dimensions including (1) core diagnostic criteria, (2) common features, (3) common medical and psychiatric comorbidities, (4) neurobiological, psychological, and functional consequences, and (5) putative neurobiological and psychosocial mechanisms, risk factors, and protective factors. This framework, comprehensively described in the study by Fillingim et al.,29 is intended for use across the lifespan with specific developmental issues and differences in signs and symptoms noted for each pain condition. As an example, Dampier et al.10 used the AAPT criteria for classifying chronic pain associated with SCD. These criteria could enhance clinical trials for pediatric SCD chronic pain by providing standardized inclusion criteria, which has been a major limiting factor in studies of pain management interventions in children and adolescents with SCD. Further work is needed to translate the AAPT classification system into a clinically useful application in the medical setting.

2.2. Recruitment considerations

Recruitment for clinical trials in pediatric pain has included various strategies from the hospital, community, primary care practices, and from tertiary care/subspecialty clinics. An advantage to recruiting from the community and primary care practices is access to patients with a range of pain and symptom severity that can make results of trials more generalizable. However, one challenge in recruiting from primary care services is that recognition and treatment of pediatric chronic pain is often not a part of pediatric primary care medical training84; hence, pediatricians are often hesitant to diagnose primary pain conditions without consulting with subspecialists to rule out other diagnoses that may be producing the pain. For example, if a child complains of recurrent headaches or abdominal pain, they are often referred to a neurologist or gastroenterologist to determine if the pain is secondary to another medical condition or disease. Recruitment from subspecialty clinics has the advantage of clearer classification/diagnosis of the pain syndrome. One potential disadvantage is that patients recruited from subspecialty/tertiary care may over-represent those with more severe or resistant symptoms or with comorbid psychiatric conditions. This could have implications for how well they respond to treatment and also make results of a trial less generalizable to those with less severe symptoms. However, choice of inclusion and exclusion criteria, as well as a focus on referrals that are directly made by primary care providers (as opposed to other specialists or second opinions) can attenuate these concerns.70,71

3. Trial design and treatment delivery

Several issues should be considered in trial design and treatment delivery in pediatric chronic pain such as inclusion of parents/caregivers, sample size, recruitment and retention challenges, novel treatment delivery settings including remote treatment delivery using digital health interventions and delivery of treatment in the school setting, and consideration of adequate control groups and placebo effects.

3.1. Inclusion of parents/caregivers

A unique aspect of clinical trials for chronic pain interventions in children is that the decision to participate in the trial as well as the receipt of treatments (eg, taking a medication or implementing a behavioral treatment) involve the parents/caregivers. We discuss specific issues pertaining to ethical requirements of parent involvement in the section on ethical issues. Because parents influence their child’s adjustment to chronic pain, they are a unique and integral part of pediatric chronic pain treatment.65 Parents also serve a critical caregiving role in administration of treatments and making decisions about health care. For medication and nonmedication trials, issues related to treatment adherence are important considerations. In particular, adolescence is a vulnerable time for nonoptimal adherence to treatment regimens,12 and concerted efforts may be needed to obtain maximal compliance, with parental supports often included. For example, a pediatric clinical trial may require participation of at least one parent who commits to attending treatment visits or who monitors medication intake as a measure of compliance in a medication trial.

In comparison with adult trials, where treatments focus primarily on the patient, an advantage (but also a complexity) to pediatric trials is the caregiver’s participation in treatment. Parent involvement can help promote engagement and facilitate a more supportive and adaptive home environment for more rapid uptake of treatment recommendations, and is recommended whenever feasible. For example, in a cross-over trial of cognitive-behavioral therapy and self-monitoring in youth with widespread musculoskeletal pain, Kashikar-Zuck et al.47 included parents in several treatment visits over the 16-week trial and had an excellent retention rate (90%), which they attributed in part to the involvement of parents. It is quite rare for adult intervention studies to be able to access the home and work environment for chronic pain treatment, which may in some ways limit the uptake or impact of treatment in daily life.

Moreover, there is considerable interest in the psychological treatment literature in the development of parent interventions for youth with chronic pain to address family communication, parent distress, and to promote change in parenting behaviors.62 In this context, the parent is seen as the agent of change and the intervention is designed to modify parent emotions, behaviors, or cognitions directly through interventions such as problem-solving therapy and cognitive-behavioral therapy interventions. Regarding trial design for these types of interventions, the parent may be the primary participant and the child may or may not receive concomitant treatment in the study. Important considerations include the choice of outcome measures to reflect parent and family outcomes targeted by the intervention as well as the intended downstream effects of parent intervention on the child’s pain and mental health outcomes.

3.2. Sample size

Despite the improving quality of trials in pediatric chronic pain in recent years, Cochrane reviews have noted the continuing methodological shortcomings due to small sample sizes.21,41,46,60 In fact, there is a paucity of trials with adequate power conducted in pediatric chronic pain from which more
decisive conclusions can be made. This is true for pediatric clinical trials in all conditions, where sample sizes typically include fewer than 100 participants. Planning a clinical trial in pediatric chronic pain raises some special concerns regarding sample size that need careful consideration. First, pediatric chronic pain is not as widely prevalent as chronic pain in adults, and there are far fewer treatment centers. Therefore, obtaining large samples of patients in a single geographic area is challenging. Hence, multisite studies are becoming increasingly common as the field advances and greater rigor is expected. This clearly raises the cost and complexity of a pediatric pain clinical trial. Multisite studies require personnel to be hired and trained in standardized procedures for assessment and treatment delivery across sites, blinding and quality control procedures often require additional staffing, centralized databases and proper database management requires extensive investments of time and funds, regulatory guidelines at different institutions can vary, and the increased emphasis on using centralized/single institutional review board or ethics committees for clinical trials (a requirement in United States National Institute of Health funded trials) can add its own complexities. However, this investment of resources is likely to pay rich dividends in terms of rigorous and definitive trials that provide clear direction for effective treatment of chronic pain in childhood—potentially altering trajectories of chronic pain and disability into adulthood and ultimately reducing the burden of chronic pain through the lifespan.

Two additional solutions to address the sample size challenges include (1) the formation of networks and registries to provide the infrastructure needed to conduct larger trials and to pool data, and (2) the use of novel designs and statistical methods to minimize sample sizes needed. International pediatric trial networks have been established in many countries. For example, in Australia, all pediatric (and adult) pain clinics are required to participate in the Electronic Persistent Pain Outcomes Collaboration (ePPOC), which involves data collection using a standard set of data items and assessment tools. In North America, the Childhood Arthritis and Rheumatology Alliance (CARRA) has 70 registry sites and is being used for patient recruitment into multicenter trials of treatments for juvenile arthritis and other pediatric rheumatic diseases. There are also several design and statistical methods that help to reduce necessary sample sizes. In pediatric pharmacokinetic studies, there are several examples of innovative trial design techniques for reducing the number and volume of samples required as well as using approaches to collect pharmacokinetic samples from children receiving treatment as part of their routine clinical care. Moreover, the use of appropriate statistical methods such as linear mixed-effects modeling to efficiently accommodate missing data can serve to maximize the value of the information obtained.

### 3.3. Recruitment and retention challenges

Participant burden is an important concern in pediatric research. Children may not have the motivation, cognitive capacity, or availability to participate in time-intensive protocols. Also, the demands of school and after-school activities, reliance on parents or other family members for transportation, and compliance in completing assessment and treatment protocols (eg, difficulty swallowing tablets) are all issues that must be considered in designing feasible trials for children with chronic pain. Parents may also be reluctant to enroll their child in a trial with unknown benefits and concerns about side effects (eg, black box warnings for antidepressant medication use in children). Moreover, there are specific pediatric pain populations for which obtaining adequate recruitment and participation in clinical trials is particularly challenging, such as in youth with SCD. In studies in the pediatric sickle cell population, who are mostly African American in the United States, low rates of recruitment (eg, as few as 13% of available samples) have been reported. Indeed, a key barrier identified to participation in intervention studies by patients with SCD is reaching them by phone and scheduling study visits. There are also significant challenges of enrolling African American youth and their parents into intervention research where broader socioeconomic barriers, including mistrust and misunderstanding of research, lack of perceived benefits from research participation, and potentially stressful home environments, may contribute to low enrollment.

In all pediatric populations, attitudes about participation in trials are important to consider. There has been general reluctance about involving children in trials because of fears of harming children by exposing them to uncertain treatment effects. A number of strategies may help address concerns about participation in clinical trials including incorporating user-centered design and community-based participatory research approaches that involve patients and other stakeholders in the research process at all levels. This approach can be particularly valuable for addressing disparities in research participation. An example of community-based participatory research in pediatric perioperative care with Latino youth undergoing surgery and their families is described by Rosales et al. with the goal to reduce disparities in perioperative intervention approaches in minority populations. To specifically address issues with participant retention, successful strategies used in pediatric clinical trials have included asking for multiple forms of contact information, providing escalating incentives for completion of multiple follow-up assessments, and using varied patient contact strategies to remind participants to complete study visits including phone, short message service text message, social media, and email. It is also essential for strategies to be used to obtain posttreatment measures on all participants, irrespective of their completion of treatment, to maximize available study data. With careful planning and involvement of stakeholders in the development of study protocols, a number of trials have demonstrated successful and timely recruitment and retention of pediatric chronic pain participants and their families.

### 3.4. Technology-based interventions

One way to reduce burden is to intervene with children with chronic pain in more naturalistic settings such as in the home through the use of digital health interventions (ie, delivered through smartphones, websites, text messaging) and to intervene in the school setting. With the almost ubiquitous availability of smartphone and computer technologies, options for delivery of pain treatments in clinical trials have expanded to include web sites, smartphone applications, and videoconferencing. For children, these forms of remote treatment delivery help to address the barriers that exist for children to participate in chronic pain intervention studies due to the geographical distance that prevents many children from attending study-related clinic visits. An emerging evidence base now exists for internet-delivered psychological interventions for chronic pain in pediatric populations, with individuals showing improvements in managing pain and disability. However, there are several specific issues with remote treatment delivery in children and adolescents that are important to consider in designing and conducting clinical trials with such treatments. Although the use
of technology may appear to be an attractive option, the specific uptake and adherence to technology-based interventions is quite variable between studies. Several strategies have been recommended to address these issues, including use of user-centered and participatory design (incorporating the end user’s perspective) and conducting usability and pilot studies to understand issues with intervention delivery and trial design before conducting larger clinical trials. Technical difficulties with technology and access for families with greater socioeconomic stress are also important considerations. For trials specifically, the missing data that may result from technical problems could lead to loss of statistical power and potential bias in treatment group comparisons. In addition to establishing efficacy, it is equally important to design trials that also establish the likely reach and uptake of digital health interventions through testing implementation, dissemination, and sustainability strategies.

3.5. School-based interventions

A potential setting for recruitment and delivery of treatment unique to pediatrics is the school setting. School is the daily “work” of children and represents an important environment for potentially delivering pain prevention and treatment. Schools may be asked to participate in psychological treatment studies (eg, by sending school attendance records or allowing the child to implement practice of behavioral skills during school hours). Moreover, there are successful examples of recruitment into clinical trials for pediatric chronic pain from schools, as well as delivery of treatment at school. For example, Larsson and Carlsson evaluated the efficacy of a school-based, nurse-administered relaxation training intervention for children with chronic tension-type headache. Developing partnerships that facilitate the conduct of clinical trials in the school setting may help to reduce burden and facilitate recruitment into pediatric chronic pain trials.

3.6. Choice of control group and placebo effects

General considerations of the trial architecture are important for enhancing rigor and providing interpretable results. In most situations, a concurrent control group is needed. Although the use of a placebo or attention control group is recommended, many pediatric trials have historically used designs that include no treatment or wait-list control groups. This is clearly a design flaw that can overestimate the effectiveness of a treatment in the absence of some type of credible control group and undermines the interpretation of data. It is recommended that trials use a control group that controls for effects of time, attention, and nonspecific factors related to experimenter–patient interaction that may influence outcomes. For example, in integrative (non-pharmacological) studies, provision of education and unsupervised or standard physical therapy exercise have been used as credible attention control conditions in pediatric chronic pain trials; in pharmacological studies, placebo or another active treatment have been most commonly used.

Another issue related to trial design in pediatric chronic pain populations is consideration of placebo effects. There is increasing recognition in pain research that placebo effects can exert a notable influence on trial outcomes in children, adolescents, and adults. This is potentially even more important in pediatric trials, given that children may have stronger placebo responses than adults. A meta-analysis of studies in pediatric migraine demonstrated prominent placebo effects in all trials, with pain relief at 2 hours ranging from 53% to 57.5%. Another meta-analysis of pharmacologic trials of pediatric headaches showed a decrease in the incidence of headaches from 5.6 to 2.9 per month in placebo groups. An example of strong placebo effects in the management of pediatric pain was recently highlighted in a large, multisite, rigorously performed randomized clinical trial of headache prevention medications vs placebo in children. Each group (amitriptyline, topiramate, and placebo) showed strong improvement with ~65% of patients achieving a clinically meaningful reduction of headaches by ≥50% at the end of 24 weeks of treatment and there were no significant differences between groups. Similarly, in the only double-blinded RCT in children with functional gastrointestinal disorders, both amitriptyline and placebo were associated with excellent therapeutic response with over 50% of the placebo group reporting improvement. Further work is clearly needed to understand mechanisms of placebo effects in pediatric chronic pain interventions.

3.7. Use of innovative clinical trial designs

Innovative clinical trial designs may be particularly important to use in pediatric chronic pain to address issues related to high patient heterogeneity in symptoms and in response to treatment, to address implementation and dissemination strategies for these populations, and as a way to maximize research questions that can be addressed within one sample. As one example, the multiphase optimization strategy framework, adapted from engineering and pioneered by Collins et al., is gaining attention in pediatric clinical trials. This is an approach that develops interventions by systematically evaluating potential treatment components to ensure that the intervention is optimized to be maximally efficient and effective. Because no treatment works for all individuals, the sequential multiple assignment randomized trial (SMART) can be used to derive decision rules (ie, algorithms) that specify how alternative interventions or intervention components should be applied optimally to meet the specific and changing needs of individuals. One advantage for its use in pediatrics is that a sequence of treatments can be studied such as whether medication can be delayed, which is often more acceptable for parents for trial participation, and can provide more information in an efficient manner within the same sample. SMART trials have been used to study sequencing in combined medication and behavioral trials in childhood anxiety and depression and attention-deficit hyperactivity disorder. An additional strategy is use of enriched enrollment designs, which have recently been described in pain clinical trials. A variation of SMART is with Enrichment (SMARTer), which recruits and randomizes additional patients to the second-stage treatments without requiring randomization of the first-stage treatments. This can reduce the sample size of the initial stage and the overall sample size needed for a SMART design. Last, innovative hybrid effectiveness-implementation trial designs are emerging in other areas of study and offer an opportunity to combine work on evaluating implementation (eg, testing of an implementation strategy) in the context of gathering information on the clinical intervention’s impact on relevant outcomes.

Although these trial designs have not yet been applied to pediatric chronic pain, they are very relevant for addressing the challenge of intervening with children with a wide range of symptom severity and disability (eg, abdominal pain or headaches that are not as yet very disabling and may respond well to minimal interventions and higher levels of care depending on response to lower levels of intervention or level of symptom severity). Moreover, such intervention designs may help to
outcome measures for test–retest reliability and sensitivity to change. As one example, Fisher et al.27 found that despite the availability, widespread use, and relevance of measures of pain-related anxiety for children and adolescents, very few had psychometric data available beyond basic internal consistency reliability statistics. Moreover, few measures have interpretable cutpoints to allow for interpretation of clinical significance of improvements. Use of 30% or 50% change in pain intensity to define clinically significant change has not been consistently applied in clinical trials in pediatric chronic pain. Often, pain intensity is not the primary outcome but rather disability is, and currently available measures of disability in children generally do not have interpretable change metrics. This has reduced knowledge of clinical improvement in many pediatric chronic pain interventions.

A new set of patient-reported outcome measures is now available with the recent validation of the PROMIS item sets in children, which have undergone a rigorous process of development and validation using modern test theory.42 An advantage of PROMIS measures is that they are not disease specific and can be used across different conditions, making comparisons across trials easier in the long run. This is important in pediatric chronic pain for pooling data in meta-analyses across limited RCTs for increased interpretability to develop evidence-based treatment guidelines. At the current time, they are being adopted with caution because the clinical interpretation of these measures and the need to develop clinically meaningful cutpoints is still in process, and the number of pediatric pain populations in which they have been tested is limited, which might limit their sensitivity. Eventually, it is expected that these short measures may allow for some consistency across trials.

4. Developmental concerns in outcome measurement and treatment delivery

Several issues should be considered in outcome measurement in children and adolescents with chronic pain including the children’s developmental level, choice of primary and secondary outcomes from core recommended domains, psychometrics of available measures, administration format of measures, choice of informant, and clinical significance of changes in outcome measures. Moreover, developmental issues are important in design and delivery of treatments across the pediatric age span, which covers a broad period of rapid physical, cognitive, and psychological changes.

4.1. Developmental level

For chronic pain conditions, most trials have focused on children aged 8 years and above because (1) that is the minimum age at which chronic pain conditions are often first identified, and (2) most children are able to read, understand, and complete outcome measures.12 It should, however, be recognized that even within a pediatric age range of 8 to 18 years, there is large variability in intellectual, social, and emotional development that can impact both assessment of outcomes and the implementation of treatments (whether medication, device, psychological, or other type).

4.2. Choice of primary and secondary outcomes

Regarding assessment, recommendations for outcome measures have been made by experts convening at a consensus conference, the Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (Ped-IMMPACT). This group identified key outcome domains that are important to assess in clinical trials with children and adolescents who have chronic or recurrent pain.57 Eight domains were recommended: pain intensity, physical functioning, symptoms and adverse events, global satisfaction with treatment, emotional functioning, role functioning, sleep, and economic factors. When available, the group recommended use of validated instruments in each of these domains. Since the publication of the Ped-IMMPACT recommendations, there has been an increase in reporting of mood and disability outcomes in trials of children with chronic pain.28 We encourage investigators to use these outcome domains as a guide, and to use consistent measures in clinical trials. Furthermore, it is relevant to highlight that these recommendations are within a larger widespread movement of recommendations to use patient-reported outcome data in clinical trials.

4.3. Psychometrics of available measures

There are a number of limitations with available pediatric outcome measures. Psychometric data on these measures are often incomplete and limited. Particularly notable are the large gaps in available psychometrics in most commonly used pediatric pain
As mentioned, this raises particular challenges for planning a pediatric trial because (1) determination of clinically meaningful change is still in its early phases for pediatric pain measures, and (2) binary endpoints typically require larger sample sizes than do continuous measures for detecting treatment effects, which raises the issue of cost and complexity of multisite studies. Of course, primary endpoints for pain outcomes should map onto the specific standards that impact clinical care (e.g., number of headache days in migraine research, \(83\) time to a pain flare in arthritis, etc.) as well as be informed by the Food and Drug Administration, and other regulatory standards typical for trials in a specific area. Funding agencies are also moving toward requirements that clinical trials must have adequate power to detect a minimal clinically meaningful difference; stakeholder feedback is needed to set such standards for pediatric chronic pain conditions to apply to clinical trials.

4.6. Developmental issues in treatment design and implementation

As mentioned above, developmental levels within the pediatric age range vary considerably and a one-size-fits-all approach to how treatments are designed and implemented cannot be expected to be successful. Designing treatments for different age groups, particularly behavioral interventions, must take into account different attentional and cognitive levels, independence in implementing treatment recommendations, and the relevance to age-appropriate interests and needs. Palermo et al.\(^{65}\) identified developmental areas across infancy/toddlerhood, middle childhood, and adolescence that may be important in pain assessment and management. In particular, issues of how best to involve parents and caregivers in treatment of the adolescent present challenges for supporting age-appropriate autonomy and independence while also providing oversight for potential adherence difficulties. Intervention content must also be engaging to the targeted age group, which can be enhanced by obtaining participation of stakeholders in reviewing intervention designs ahead of trials. Moreover, given the smaller available samples for many pediatric chronic pain conditions, there is a tendency for investigators to want to use wide age ranges (e.g., 8 to 17 years) to maximize enrollment, which unfortunately runs the risk of inappropriate intervention design and delivery at each end of the range. In general, age effects need to be considered in statistical models, and when possible, study designs should use age stratification, and consider narrow, developmentally defined age groups in trials.

5. Ethical considerations

Ethical considerations of clinical trials in children with chronic pain include both general issues pertaining to inclusion of vulnerable populations as well as specific issues related to the conduct of the trial. The obligation to conduct clinical trials to improve children’s health and protect them from the risk of using untested interventions must be balanced against protecting children against unknown risks and harms from participation in a clinical trial. Ethical guiding principles in trials for children and adolescents are the same as for adults with chronic pain, and include adhering to the values of respect, patient autonomy and beneficence, nonmaleficence, and justice.\(^{35}\) There are additional ethical considerations in pediatric trials, however, because children lack the capacity to understand the risks involved in trials and depend on adults to make decisions for them. There are also additional protections in place for children to guard against potential harms.

5.1. Informed consent

Informed consent for participation in pediatric trials is more complex than for adult studies because consent is by proxy from the parent or guardian, who have a duty to protect the child’s welfare. In the United States, once children reach 18 years, they are legally able to provide their own consent for study participation; for studies in which participation crosses this age threshold (e.g., youth turn 18 years during the study), their reconsent must be obtained at that time point. Regulatory requirements for research involving children include both obtaining and documenting the assent of children (who are cognitively able to provide it) and the consent of the child’s guardian. Children’s autonomy should be respected and every effort should be made to respect their decision on study participation. There has been some work on developing strategies to aid parents in the decision-making process for trial participation such as improving the readability of the consent document and using innovative methods such as video explanations of study protocols.\(^{36}\) One trial in pediatric SCD instituted a peer patient navigator to reduce barriers to study participation and facilitate understanding of the clinical trial,\(^{17}\) which may be especially useful for enhancing recruitment in minority populations. Increasingly, the importance of engaging children and families in the recruitment, consent, and design of trials has been recognized.\(^{6}\)

In addition, the risks and burdens of trial participation must be minimized for children. For example, to protect children from unnecessary testing, the volume of blood sampling generally allowed in pediatric trials is lower than in adults, and it is recommended to obtain samples during routine clinical care whenever possible. Moreover, parents and youth consistently raise study demands as barriers to participation in clinical trials,\(^{4,67}\) and thus, strategies to minimize burden are critical in pediatric trials. The majority of parents (91.5%) accept the idea of using placebos in pediatric trials and would prefer enrolling their child in a trial using placebo than in a trial testing the new drug against an already existing drug with possible side effects.\(^{24}\)

5.2. Trial registration and publication

It is an ethical obligation in research for investigators to uphold transparency in the conduct of their trials and to report results through trial registration and publication. All clinical trials should be registered before patient enrollment although an alarmingly high number do not adhere.\(^{34}\) Trial discontinuation and nonpublication represent potential waste in resources and have been documented to be a significant problem in pediatric trials, with almost 30% of completed trials not published.\(^{58}\) Although not unique to pediatric trials, another important problem identified in pain and anesthesiology clinical trials is accurate, a priori identification of primary and secondary outcome measures.\(^{30,43}\) Reviewers and editors serve an important role in identifying issues such as these that compromise interpretability of clinical trials. Given the overall more limited number of pediatric clinical trials, it is particularly important to encourage transparency of trial conduct and reporting of results in investigations in pediatric chronic pain. Researchers seeking to conduct clinical trials of chronic pain interventions in children must consider relevant ethics in the design, implementation, and dissemination of their trials.

6. Recommendations and conclusions

As we have highlighted, important considerations exist in designing and conducting clinical trials of chronic pain interventions in children and adolescents, including issues pertaining
Table 1
Summary of key recommendations for design and implementation of clinical trials of chronic pain interventions in children and adolescents.

| Domain                                             | Common Issues                                                                 | Recommended strategies                                                                 |
|----------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Sample characterization                           | Limited prevalence of some well-characterized adult pain conditions            | Use available consensus definitions when possible (e.g., ROME criteria for functional GI disorders) |
|                                                   | Differences in clinical signs, symptoms, and comorbidities as in adults       | Use evidence-based chronic pain classification systems when available (ACTTION-APS Pain Taxonomy, AAPT) |
|                                                   | Lack of available consensus definitions of pediatric chronic pain disorders   | Develop inclusion and exclusion criteria to ensure that these diagnoses (or at least clinical elevations of symptoms) are present in the sample |
|                                                   | Heterogeneity of pediatric chronic pain samples including variability in symptoms and impairment | Consider inclusion of referrals from primary care and clear inclusion/exclusion criteria to guide referral process |
|                                                   | Recruitment from tertiary care/subspecialty clinics may limit generalizability of trial results |                                                                                         |
| Trial design and treatment delivery               | How best to involve parents/caregivers in helping to increase child adherence to the intervention or in receiving their own parent intervention | Involve parents in treatment visits whenever feasible                                  |
|                                                   | Lack of adequately powered trials due to small sample sizes                   | Consider including appropriate parent or family outcome or process measures (e.g., behavior, distress) based on intended focus of the intervention |
|                                                   | Recruitment and retention challenges due to study burden, parent and child attitudes about trial participation, and barriers present in minority populations | Plan for multisite studies; when possible, use available networks or registries       |
|                                                   | Use of designs that include no treatment or wait-list control groups           | Consider the use of novel designs and appropriate statistical methodology (e.g., linear mixed-effects modeling) to address missing data and sample size challenges. |
|                                                   | Children may have stronger placebo response to intervention than adults       | Improve recruitment and retention by obtaining multiple forms of contact, provide escalating incentives, and use varied contact strategies (e.g., text, email) |
|                                                   | Designing interventions to treat children with wide range of symptom severity and disability with available samples | Consider community-based participatory research (CBPR) to address patient disparities |
|                                                   |                                                                              | Reduce burden by intervening in naturalistic settings (internet-based studies, school setting) |
|                                                   |                                                                              | Use placebo or attention control group to control for effects of time, attention, and potential none specific factors of intervention (experimenter–patient interaction) |
|                                                   |                                                                              | Consider innovative clinical trial designs (e.g., SMART designs) to address heterogeneity in patient symptoms and to maximize information gained from one sample |
| Developmental concerns in outcome measurement and treatment delivery | Limitations with available pediatric outcome measures including lack of psychometric data and lack of clinically interpretable cutpoints | Use Ped-IMMPACT recommendations to guide choice of relevant outcome domains |
|                                                   | When to use self-report vs parent proxy for outcome measures                  | Need to further validate measures for pediatric chronic pain populations               |
|                                                   | Use of wide age ranges (e.g., 8–17 y)                                        | Use primary endpoints for pain that map onto the specific standards that impact clinical care for specific populations |
|                                                   |                                                                              | Obtain child self-report on outcome measures when possible                             |
|                                                   |                                                                              | Use age stratification in study designs; use narrow, developmentally defined age groups; incorporate age effects in statistical models |

(continued on next page)
to sample characterization, treatment administration, development of outcomes measurement and treatment, and in the ethics of conducting chronic pain trials in children and adolescents. Table 1 summarizes key issues and provides recommendations for addressing them in clinical trials of chronic pain interventions in children and adolescents. Clearly, this is an evolving field and we hope that this article stimulates further discussion of best practices in the design and conduct of clinical trials for children and adolescents with chronic pain.

It is important to also emphasize the obligation of quality reporting of clinical trials of chronic pain interventions in children and adolescents. As mentioned, issues of adequate trial registration, nonpublication, and switching of primary outcomes in the analysis phase are all important issues. Moreover, many published trials in children and adolescents have been classified as low quality due to high or unclear risk of bias in other design elements (eg, use of wait-list control conditions). This is in part due to methodological limitations of trial designs but also in part due to lack of proper attention to reporting standards for randomized (CONSORT) and nonrandomized trials (TREND). Greater attention to trial quality and reporting conventions will greatly enhance the literature and confidence in the evidence base for the best treatments for pediatric chronic pain. There are exemplary pediatric chronic pain trials with low risk of bias that can serve as models for design and reporting standards.

**Disclosures**

The authors have no conflict of interest to declare.

T.M. Palermo is supported in part by Grant no. K24HD060068 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

**Article history:**

Received 30 November 2017

Received in revised form 21 February 2018

Accepted 3 March 2018

**References**

[1] Almirall D, Chronis-Tuscano A. Adaptive interventions in child and adolescent mental health. J Clin Child Adolesc Psychol 2016;45:383–95.

[2] Andrasik F, Powers SW, McGrath PJ. Methodological considerations in research with special populations: children and adolescents. Headache 2006;45:520–5.

[3] APS Task Force on Children’s Pain. Assessment and management of children with chronic pain. A Position Statement from the American Pain Society. 2012.

Available at: http://americanpainsociety.org/uploads/get-involved/pediatric-chronic-pain-statement.pdf. Accessed on November 13, 2017.

[4] Barakat LP, Schwartz LA, Reilly A, Deatrick JA, Batts F. A qualitative study of phase III cancer clinical trial enrollment decision-making: perspectives from adolescents, young adults, caregivers, and providers. J Adolesc Young Adult Oncol 2014;3:3–11.

[5] Barakat LP, Schwartz LA, Salamon KS, Radcliffe J. A family-based randomized controlled trial of pain intervention for adolescents with sickle cell disease. J Pediatr Hematol Oncol 2010;32:540–7.

[6] Bartholome WG. Informed consent, parental permission, and assent in pediatric practice. Pediatrics 1995;96(6 pt 1):981–2.

[7] Berde CB, Walco GA, Kraner EJ, Anand KJ, Aranda JV, Craig KD, Dampier CD, Finkel JC, Graboid M, Johnston C, Lantos J, Lebel A, Maxwell MG, McGrath P, Oberlander TF, Schanberg LE, Stevens B, Taddio A, von Baeyer CL, Yaster M, Zempsky WT. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics 2012;129:564–6.

[8] Bourgeois FT, Murphy S, Pinto C, Olson KL, Ioannidis JP, Mandi KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 2012;130:285–92.

[9] Buck D, Hogan V, Powell CJ, Sloper JJ, Speed C, Taylor RH, Tiffin P, Clarke MP. Surrendering control, or nothing to lose: parents’ preferences about participation in a randomised trial of childhood strabismus surgery. Clin Trials 2015;12:384–93.

[10] Buscemi J, Blumstein L, Kong A, Stolley MR, Schiffer L, Odoms-Young A, Bittner C, Fitzgibbon M. Retaining traditionally hard to reach participants: lessons learned from three childhood obesity studies. Contemp Clin Trials 2015;42:98–104.

[11] Cohen E, Goldmand RD, Ragone A, Ulerky E, Atenafu EG, Siddiqui U, Mahmoud N, Parkin PC. Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985–2005. Arch Pediatr Adolesc Med 2010;164:283–8.

[12] Cohen LL, Lermanek K, Blount RL, Dahlquist LM, Lin CS, Palermo TM, McKenna KD, Weiss KE. Evidence-based assessment of pediatric pain. J Pediatr Psychol 2008;33:939–55.

[13] Collins LM, Baker TB, Mermelstein RJ, Piper ME, Jorenby DE, Smith SS, Christiansen BA, Schlam TR, Cook JW, Fore MC. The multiphasic optimization strategy for engineering effective tobacco use interventions. Ann Behav Med 2011;41:238–46.

[14] Collins LM, Nahum-Shani I, Almirall D. Optimization of behavioral dynamic treatment regimens based on the sequential, multiple assignment, randomized trial (SMART). Clin Trials 2014;11:426–34.

[15] Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care 2012;50:217–26.

[16] Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. APT diagnostic criteria for chronic sickle cell disease pain. J Pain 2017;18:490–8.

[17] Daniel LC, Li Y, Smith K, Tarazi R, Robinson MR, Patterson CA, Smith-Whiteley K, Stuart M, Barakat LP. Lessons learned from a randomized controlled trial of a family-based intervention to promote school functioning for school-age children with sickle cell disease. J Pediatr Psychol 2015;40:1085–94.

[18] Davidson AJ, Disma N, de Graaff JC, Whitington DE, Dorris L, Bell G, Stargatt R, Bellinger DC, Schuster T, Armup SJ, Hardy P, Hunt RW, Takagi...
Hechler T, Ruhe AK, Schmidt P, Hirsch J, Wager J, Dobe M, Hazen RA, Eder M, Drotar D, Zyzanski S, Reynolds AE, Reynolds CP, Hamm MP, Hartling L, Milne A, Tjosvold L, Vandermeer B, Thomson D, Groenewald CB, Essner BS, Wright D, Fesinmeyer MD, Palermo TM. The Goldman RD, Mounstephen W, Kirby-Allen M, Friedman JN. Intravenous Friedrichsdorf SJ, Giordano J, Desai-Dakoji K, Warmuth A, Schulz CA. Fisher E, Heathcote LC, Eccleston C, Simons LE, Palermo TM. Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Fichtel A, Larsson B. Does relaxation treatment have differential effects on Faria V, Kossowsky J, Petkov MP, Kaptchuk TJ, Kirsch I, Lebel A, Elnaggar RK, Elshafey MA. Effects of combined resistive underwater Eccleston C, Malleson PN, Clinch J, Connell H, Sourbut C. Chronic pain in children with chronic pain. A systematic review and meta-analysis. J Pediatr Psychol 2014;39:492–501. Kashikar-Zuck S, Swan NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile fibromyalgia syndrome. J Pediatrics 2013;132:1634–41. Friedrichsdorf SJ, Giordano J, Desai-Dakoji K, Warnath A, Schulz CA. Chronic pain in children and adolescents: diagnosis and treatment of primary pain disorders in head, abdomen, muscles and joints. Children (Basel) 2016;3:642. Groenewald CB, Essner BS, Wright D, Fesinmeyer MD, Palermo TM. The economic costs of chronic pain among a cohort of treatment-seeking adolescents in the United States. J Pain 2014;15:925–33. Hammond MP, Hartling L, Mine A, Tjosvold L, Vandermeer B, Thomson D, Currie S, Klassen TP. A descriptive analysis of a representative sample of pediatric randomized controlled trials published in 2007. BMC Pediatr 2010;10:96. Harris PA, Taylor PR, Thieleke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics infrastructure support. J Biomed Inform 2009;42:377–81. Hazen RA, Eder M, Drotar D, Zyzański S, Reynolds AE, Reynolds CP, Kodish E, Noll RB. A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia. J Pediatr Hematol Oncol 2009;31:269–74. Headache Classification Committee of the International Headache Society. The international Classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808. Hechter T, Ruhe AK, Schmidt P, Hirsch J, Wager J, Dobe M, Krummenera F, Zernikow B. Inpatient-based intensive interdisciplinary pain treatment for highly impaired children with severe chronic pain: randomized controlled trial of efficacy and economic effects. PAIN 2014;155:118–28. Hicks CL, von Baeyer CL, McGrath PJ. Online psychological treatment for pediatric recurrent pain: a randomized evaluation. J Pediatr Psychol 2006;31:724–36. Huguet A, Miro J. The severity of chronic pediatric pain: an epidemiological study. J Pain 2008;9:226–36. Huguet A, Tougas ME, Hayden J, McGrath PJ, Stinson JN, Chambers CT. Systematic review with meta-analysis of childhood and adolescent risk and prognostic factors for musculoskeletal pain. PAIN 2016;157: 2640–57. Levine HD, Suckdy BD, Thissen D, Dewitt EM, Lai JS, Yeatts K, Varni JW, DeWalt DA. Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res 2010;19:585–94. Jones PM, Chow JTY, Arango MF, Fridfinnson JA, Gai N, Lam TP, Turkstra TP. Comparison of registered and reported outcomes in randomized clinical trials published in anesthesiology journals. Anesth Analg 2017;125:1592–900. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol 2015;79:357–69. Kashikar-Zuck S, King C, Ting TV, Arnold LM. Juvenile fibromyalgia: different from the adult chronic pain syndrome? Curr Rheumatol Rep 2016;18:19. Kashikar-Zuck S, Sil S, Lynch-Jordan AM, Ting TV, Peugh J, Schikler KN, Hashkes PJ, Arnold LM, Passo M, Richards-Mauze MM, Powers SW, Lovell DJ. Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia. J Pain 2013;14:492–501. Kashikar-Zuck S, Swan NF, Jones BA, Graham TB. Efficacy of cognitive-behavioral intervention for juvenile primary fibromyalgia syndrome. J Rheumatol 2005;32:1594–602. Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, Passo M, Schikler KN, Hashkes PJ, Spalding S, Lynch-Jordan AM, Banez G, Richards MM, Lovell DJ. Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum 2012;64:297–305. Keefe FJ, Crossman DA, Guthrie E, Simon M, Tillisch K, Olden K, Whorwell PJ. Centrally mediated disorders of gastrointestinal pain. Gastroenterology 2016;150:5085–96. King S, Chambers CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, MacDonald AJ. The epidemiology of chronic pain in children and adolescents revisited: a systematic review. PAIN 2011;152:2729–38. Larsson B, Carlsson J. A school-based, nurse-administered relaxation training for children with chronic tension-type headache. J Pediatr Psychol 1996;21:603–14. Larsson B, Carlsson J, Fitchel A, Melin L. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache 2005;45:692–704. Leonard A, Hutchesson M, Patterson A, Chalmers K, Collins C. Recruitment and retention of young women into nutrition research studies: practical considerations. Trials 2014;15:23. Liu Y, Wang Y, Zeng D. Sequential multiple assignment randomization trials with enrichment design. Biometrics 2017;73:376–90. Logue DE, Carpino EA, Chiang G, Condon M, Fin E, Gauyhan VJ, Hogan M, Leslie DS, Olson K, Saper S, Sethna N, Simon LE, Zurakowski D, Berde CB. A day-hospital approach to treatment of pediatric complex regional pain syndrome: initial functional outcomes. Clin J Pain 2012;28:766–74. Maynard CS, Amari A, Wieczorek B, Christensen JR, Stifer KJ. Interdisciplinary behavioral rehabilitation of pediatric pain-associated disability: retrospective review of an inpatient treatment protocol. J Pain 2014;15:128–37. McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, Eccleston C, Finley GA, Goldschneider K, Haverkos L, Hertz SH, Ljungman G, Palermo T, Rappaport BA, Rhodes T, Schechter N, Scott J, Sethna N, Svensson OK, Stinson J, von Baeyer CL, Walker L, Weisman S, White RE, Zajicek A, Zeltzer L. Core outcome domains and measures for pediatrician acute and chronic/recurrent pain clinical trials: PedIMEPPACT recommendations. J Pain 2008;9:771–83. Moore RA, Wiffen PJ, Eccleston C, Eccleston C, Derry S, Baron R, Bell RF, FurLAN AD, Gilron I, Haroutounian S, Katz NP, Lipman AG, Morley S, Peloso PM, Quessy SN, Seers K, Strassels SA, Straube S. Systematic review of enriched enrolment, randomised withdrawal trials in chronic pain: a new framework for design and reporting. PAIN 2015;156: 1382–95. Palermo TM. Impact of recurrent and chronic pain on child and family daily functioning: a critical review of the literature. J Dev Behav Pediatr 2000; 21:58–69.
[60] Palermo TM, Eccleston C, Lewandowski AS, Williams AC, Morley S. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. PAIN 2010;148:387–97.

[61] Palermo TM, Jamison RN. Innovative delivery of pain management interventions: current trends and future progress. Clin J Pain 2015;31:467–9.

[62] Palermo TM, Law EF, Bromberg M, Fales J, Eccleston C, Wilson AC. Problem-solving skills training for parents of children with chronic pain: a pilot randomized controlled trial. PAIN 2016;157:1213–23.

[63] Palermo TM, Law EF, Fales J, Bromberg MH, Jessen-Fiddick T, Tai G. Internet-delivered cognitive-behavioral treatment for adolescents with chronic pain and their parents: a randomized controlled multicenter trial. PAIN 2016;157:174–85.

[64] Palermo TM, Scher MS. Treatment of functional impairment in severe somatoform pain disorder: a case example. J Pediatr Psychol 2001;26:429–34.

[65] Palermo TM, Valier CR, Carlson CW. Family and parent influences on pediatric chronic pain: a developmental perspective. Am Psychol 2014;69:142–52.

[66] Palermo TM, Wilson AC, Peters M, Lewandowski A, Somhegyi H. Randomized controlled trial of an internet-delivered family cognitive-behavioral therapy intervention for children and adolescents with chronic pain. PAIN 2009;146:205–13.

[67] Patterson CA, Chavez V, Mondesert V, Deatrick J, Li Y, Barakat LP. Clinical trial decision making in pediatric sickle cell disease: a qualitative study of perceived benefits and barriers to participation. J Pediatr Hematol Oncol 2015;37:415–22.

[68] Pelham WE Jr, Fabiano GA, Waxmonsky JG, Greiner AR, Gnagy EM, Pelham WE, Coxe S, Verley J, Bhatia I, Hart K, Karch K, Konijendijk E, Tresco K, Nahurn-Shani I, Murphy SA. Treatment sequencing for childhood ADHD: a multiple-randomization study of adaptive medication and behavioral interventions. J Clin Child Adolesc Psychol 2016;45:396–415.

[69] Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics 2016;138:e20160223.

[70] Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115–24.

[71] Powers SW, Kashkar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, Kabbourche MA, O’Brien HL, Shenk CE, Rausch JR, Hershey AD. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA 2013;310:2622–30.

[72] Ramsay RR, Ryan JL, Hershey AD, Powers SW, Aylward BS, Hommel KA. Treatment adherence in patients with headache: a systematic review. Headache 2014;54:795–816.

[73] Roohafza H, Adlard K, Kain ZN. Community-based participatory research: an innovative approach for improving perioperative care of underserved children. Paediatr Anaesth 2017;27:126–36.

[74] Rosenbloom BN, Rabbits JA, Palermo TM. A developmental perspective on the impact of chronic pain in late adolescence and early adulthood: implications for assessment and intervention. PAIN 2017;158:1629–32.

[75] Rutten JM, Vlieger AM, Frankenhuysen C, George EK, Groeneweg M, Nordruis CF, Tjon a Ten W, Van Wering H, Dijkgraaf MG, Merkus MP. Beninga MA. Gut-directed hypnotherapy in children with irritable bowel syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr 2014;14:140.

[76] Sapa M, Youssef N, Miranda A, Nurko S, Hyman P, Coccin J, Di Lorenzo C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009;137:1261–9.

[77] Schatz J, Schlenz AM, McClellan CB, Puffer ES, Hardy S, Pfeiffer M, Roberts CW. Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain 2015;31:536–47.

[78] Schechter NL. Functional pain: time for a new name. JAMA Pediatr 2014;168:693–4.

[79] Schlenz AM, Schatz J, Roberts CW. Examining biopsychosocial factors in relation to multiple pain features in pediatric sickle cell disease. J Pediatr Psychol 2016;41:930–40.

[80] Stevens EM, Patterson CA, Li YB, Smith-Whitley K, Barakat LP. Mistrust of pediatric sickle cell disease clinical trials research. Am J Prev Med 2016;51(1 suppl 1):S78–86.

[81] Sun H, Bastings E, Temeck J, Smith PB, Men A, Tandon V, Murphy D, Rodriguez W. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr 2013;167:243–9.

[82] Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6–38.

[83] Thompson LA, Knapp CA, Feeg V, Madden VL, Shenkman EA. Pediatricians’ management practices for chronic pain. J Pediatr 2016;13:171–8.

[84] Walco GA, Kranz JE, Schmader KE, Weiner DK. Applying a lifespan developmental perspective to chronic pain: pediatrics to geriatrics. J Pain 2010;11:506–17.

[85] Walker LS, Dengler-Crish CM, Rippel S, Bruehl S. Functional abdominal pain syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr 2014;14:140.

[86] Walker LS, Dengler-Crish CM, Rippel S, Bruehl S. Functional abdominal pain in childhood and adolescence increases risk for chronic pain in adulthood. PAIN 2010;150:568–72.

[87] Wicksell RK, Melin L, Lekander M, Olsson GL. Evaluating the effectiveness of exposure and acceptance strategies to improve functioning and quality of life in longstanding pediatric pain–a randomized controlled trial. PAIN 2009;148:387–97.

[88] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. PAIN 2011;152(3 suppl):S2–15.

[89] Wu YP, Steele RG, Connelly MA, Palermo TM, Ritterband LM. Commentary: pediatric eHealth interventions: common challenges during development, implementation, and dissemination. J Pediatr Psychol 2014;39:612–23.